Stock Price Forecast The 5 analysts offering 12-month price forecasts for Savara Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +143.90% increase from the last price of 1.23.
Is SVRA a buy?
The financial health and growth prospects of SVRA, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is savara a good stock to buy?
Fair opening price Current price
----------------------------------- ------------------
$1.13 $1.14 (Overvalued)
Why is savara stock dropping?
Shares in Savara Inc. SVRA, -2.56% , which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target. When shares were reopened for late trading, the price immediately fell to less than $2.40.
What is the forecast for Xpeng stock?
Stock Price Forecast The 20 analysts offering 12-month price forecasts for Xpeng Inc have a median target of 58.79, with a high estimate of 92.34 and a low estimate of 27.26. The median estimate represents a +61.72% increase from the last price of 36.35.
What does Savara Inc do?
Savara Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the development of novel therapies for the treatment of serious and life-threatening rare respiratory diseases. Savara offers its services worldwide.